Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure

被引:52
作者
Abouzahr, S
Bismuth, G
Gaudin, C
Caroll, O
Van Endert, P
Jalil, A
Dausset, J
Vergnon, I
Richon, C
Kauffmann, A
Galon, J
Raposo, G
Mami-Chouaib, F
Chouaib, S
机构
[1] Inst Gustave Roussy, Inst Natl Sante & Rech Med, U487, F-94805 Villejuif, France
[2] Univ Paris 05, UMR 8104, CNRS, Inst Cochin,Inst Natl Sante Rech Med,U567, F-75014 Paris, France
[3] Univ Paris 05, Inst Natl Sante & Rech Med, U580, Paris, France
[4] CNRS, UMR 144, Inst Curie, Res Sect, F-75248 Paris 5, France
[5] Inst Natl Sante & Rech Med, Ctr Rech Biomed Cordeliers, U255, F-75006 Paris, France
[6] Inst Gustave Roussy, UMR 8125, CNRS, F-94805 Villejuif, France
[7] Ctr Etud Polymorphisme Humain, F-75010 Paris, France
关键词
cell-mediated cytotoxicity; ephrin-A1; scinderin;
D O I
10.1073/pnas.0510454103
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To investigate tumor resistance to T cell lysis, a resistant variant was selected after specific cytolytic T lymphocytes (CTL) selection pressure. Although the resistant variant triggered perforin and granzyme B transcription in specific CTLs, as well as their degranulation, it exhibited a dramatic resistance to cytotoxic T cell killing. It also displayed strong morphological changes with alterations of the actin cytoskeleton. Electron microscopy analysis revealed a loosen interaction between CTLs and the resistant variant despite the formation of apparently normal conjugates. Transcriptional profiling identified a gene expression signature that distinguished sensitive from resistant tumor targets. More notably, we found that actin-related genes ephrin-A1 and scinderin were overexpressed in resistant target. Silencing of these genes using RNA interference resulted in a restoration of normal cell morphology and a significant attenuation of variant resistance to CTL killing. Our present study shows that a shift in cytoskeletal organization can be used, by tumor cells, as a strategy to promote their resistance after CTL selection pressure.
引用
收藏
页码:1428 / 1433
页数:6
相关论文
共 40 条
  • [1] Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO
  • [2] 2-Y
  • [3] Dynamic molecular interactions linking the T cell antigen receptor to the actin cytoskeleton
    Barda-Saad, M
    Braiman, A
    Titerence, R
    Bunnell, SC
    Barr, VA
    Samelson, LE
    [J]. NATURE IMMUNOLOGY, 2005, 6 (01) : 80 - 89
  • [4] MOLECULAR CHARACTERIZATION OF A FAMILY OF LIGANDS FOR EPH-RELATED TYROSINE KINASE RECEPTORS
    BECKMANN, MP
    CERRETTI, DP
    BAUM, P
    VANDENBOS, T
    JAMES, L
    FARRAH, T
    KOZLOSKY, C
    HOLLINGSWORTH, T
    SHILLING, H
    MARASKOVSKY, E
    FLETCHER, FA
    LHOTAK, V
    PAWSON, T
    LYMAN, SD
    [J]. EMBO JOURNAL, 1994, 13 (16) : 3757 - 3762
  • [5] BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
  • [6] SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity
    Bots, M
    Kolfschoten, IGM
    Bres, SA
    Rademaker, MTGA
    de Roo, GM
    Krüse, M
    Franken, KLMC
    Hahne, M
    Froelich, CJ
    Melief, CJM
    Offringa, R
    Medema, JP
    [J]. BLOOD, 2005, 105 (03) : 1153 - 1161
  • [7] Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems
    Caplen, NJ
    Parrish, S
    Imani, F
    Fire, A
    Morgan, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) : 9742 - 9747
  • [8] EphrinA1-induced cytoskeletal re-organization requires FAK and p130cas
    Carter, N
    Nakamoto, T
    Hirai, H
    Hunter, T
    [J]. NATURE CELL BIOLOGY, 2002, 4 (08) : 565 - 573
  • [9] The host-tumor immune conflict: from immunosuppression to resistance and destruction
    Chouaib, S
    AsselinPaturel, C
    MamiChouaib, F
    Caignard, A
    Blay, JY
    [J]. IMMUNOLOGY TODAY, 1997, 18 (10): : 493 - 497
  • [10] DAVEANU L, 2005, NAT IMMUNOL, V6, P689